Clinical Trial Update: A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of alectinib and duvelisib in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Drugs mentioned

• Alecensa (alectinib)
• Duvelisib (duvelisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma | Phase 1 | Status: RECRUITING